Does This Patient Have Volume Overload? The Rational Clinical Examination

Overweight and obesity may cause 10% of new cancer diagnoses annually in the US. In this JAMA Review in the Translational Science series, author Neil Iyengar, MD, of Emory University discusses the biological pathways that may promote cancer in people with overweight or obesity and potential therapies with JAMA Deputy Editor Mary McDermott, MD. Related Content: Obesity and Cancer

Chronic noninfectious diarrhea affects approximately 6% to 7% of adults in the US and significantly impairs quality of life. Author William Chey, MD, of the University of Michigan joins JAMA Deputy Editor Mary M. McDermott, MD, to discuss strategies for diagnosis and treatment of chronic, noninfectious diarrhea. Related Content: Chronic, Noninfectious Diarrhea

Accurate assessment of intravascular volume facilitates decisions about fluid management in patients with volume overload. Author Edmund A. Liles Jr, MD, of the University of Utah joins JAMA Associate Editor David Simel, MD, MHS, to discuss best evidence from physical exam findings including ultrasound, radiographs, and lab studies for determining volume overload in spontaneously breathing patients. Related Content: Does This Patient Have Volume Overload?

Type 1 diabetes affects approximately 2 million people in the US and 8.4 million people worldwide. Author Desmond Schatz, MD, of the University of Florida joins JAMA Deputy Editor Mary M. McDermott, MD, to discuss current evidence regarding diagnosis and treatment of type 1 diabetes. Related Content: Type 1 Diabetes

Mark Cuban, entrepreneur, investor, and cofounder of the Mark Cuban Cost Plus Drug Company, joins JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, to discuss the role of pharmacy benefit managers, insurance formularies, and opaque pricing practices that shape how most Americans access prescription drugs. Hear why he thinks doctors are the good guys in a broken system. Related Content: Pharmaceutical Pricing—JAMA Talks With Mark Cuban

Opioid use disorder is the third most prevalent substance use disorder worldwide. Author Alexander Walley, MB, MSc, of Boston Medical Center and Boston University joins JAMA Deputy Editor Kristin Walter, MD, MS, to discuss the efficacy, safety, and practical considerations of treating patients with medications for opioid use disorder, opioid withdrawal, and opioid overdose. Related Content: Medications for Opioid Use Disorder, Opioid Withdrawal, and Opioid Overdose

Ovarian cancer may be prevented with removal of the fallopian tubes during pelvic or select abdominal surgery in eligible women. This procedure, opportunistic salpingectomy, can be offered to more eligible women. Author Jurgen M. Piek, MD, PhD, of the Catharina Cancer Institute discusses this and more with JAMA Deputy Editor Linda Brubaker, MD, MS. Related Content: Opportunistic Salpingectomy for Prevention of Tubo-Ovarian Carcinoma

IgA nephropathy is a chronic kidney disease involving deposition of IgA-containing immune complexes in the glomerulus, which often causes kidney failure within 10 to 20 years. Author Michelle Marie O'Shaughnessy, MB, BCh, BAO, MS, of Galway University joins JAMA Deputy Editor Kristin Walter, MD, MS, to discuss the symptoms, risk factors, diagnosis, treatment, and prognosis of IgA nephropathy in adults. Related Content: IgA Nephropathy in Adults

Restless legs syndrome is a sleep-related neurologic disorder that causes an overwhelming urge to move the limbs, which can cause substantial sleep disturbance. Author John W. Winkelman, MD, PhD, of Harvard Medical School joins JAMA Deputy Editor Kristin Walter, MD, MS, to discuss the symptoms, risk factors, diagnosis, and treatment of restless legs syndrome. Related Content: Restless Legs Syndrome

Mifepristone used with misoprostol is the most common abortion regimen in the US. It is also a focal point of reproductive health policy and politics, with controversy over its legal status and regulation by the US Food and Drug Administration (FDA). Author G. Caleb Alexander, MD, MS, from Johns Hopkins discusses this and more with JAMA Deputy Editor Joseph S. Ross, MD, MHS. Related Content: The US Food and Drug Administration's Regulation of Mifepristone Politics, Science, and the Future of FDA Drug Regulation